## ANTIFUNGAL SUSCEPTIBILITY OF CANINE AND FELINE *MALASSEZIA* SPP. ISOLATES TO LACTOFERRICIN: PRELIMINARY IN-VITRO STUDY E. Biasibetti \*, A. Corona<sup>†</sup>, F. Valenza \*, F. Dosio<sup>‡</sup>, N. Bruni<sup>§</sup>and M.T. Capucchio

\*Department of Veterinary Sciences, University of Torino, Torino, †Ambulatorio Veterinario Associato, Torino,

<sup>‡</sup>Department of Drug Science and Technology, University of Torino, Torino and <sup>§</sup>Istituto Farmaceutico Candioli, Beinasco, Torino, Italy

**Introduction**: *Malassezia* spp. is a fungus isolated from the skin and mucosae of dogs and cats, which may cause dermatitis and otitis. Therapies include the use of antibiotics, antifungals and glucocorti-coids. Because of the antibiotic-resistance phenomenon, new alterna-tive therapies are necessary. Bovine lactoferricin (Lfc) is a peptide derived from proteolytic cleavage of lactoferrin with proven antibac-terial, antifungal and immunostimulatory activity. The aim of this study was to evaluate the antifungal susceptibility of *Malassezia* spp. to Lfc-Candioli Pharma (water solution 20%) using a microdilution method.

**Materials and Methods**: Fifty strains of *Malassezia* spp. collected from 50 animals (five cats, 45 dogs) affected by dermatitis and/or otitis externa and classified based on clinical signs and/or skin biopsies were cultured on Sabouraud's dextrose broth. Minimal inhibitory concentrations of Lfc were measured using the following concentra-tions: 13.3%, 10%, 6.7 %, 3.3% and 1.8%. Plates were incubated at 35°C and read 4 days after inoculation. To check the reproducibility of the

procedure, all of the isolates were double tested and qual-ity controls were performed.

**Results**: All isolates were inhibited by Lfc with different minimum inhibitory concentration value. The product showed antifungal effi-cacy of 100% up to a dilution corresponding to 10% of Lfc.

The first resistance was observed from 6.7% to the total resistance of 1.8%.

**Conclusions**: These results suggest a potential antifungal efficacy of Lfc *in vivo*, even if in-vitro data should be considered with caution un-til standardized methods and correlation with clinical outcomes has been evaluated.